3D-printed bioactive scaffolds with alginate hydrogel and stromal vascular fraction differentiated into osteoblasts applied to bone repair.
Jayme CC., Fernandes DS., Matsuo FS., Osako MK., Tedesco AC.
Animal Study, published in J Mech Behav Biomed Mater (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Mech Behav Biomed Mater (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42096881
- DOI
- 10.1016/j.jmbbm.2026.107449
Abstract (original English)
Bone injuries present enormous medical challenges worldwide. Most scaffolds used in tissue engineering do not possess an appropriate combination of properties inherent to bone tissue, such as elasticity, rigidity, biocompatibility, osteoinductivity, and antimicrobial properties. In this study, we constructed a bioprinted scaffold using polycaprolactone (PCL), polyethylene glycol (PEG), and alginate cellular carrier hydrogels. This scaffold is associated with the stromal vascular fraction (SVF), a heterogeneous cell population rich in adipose-derived stem cells and contains osteogenic differentiation factors that promote bone repair. The successful construction of the PCL-PEG-based scaffold was confirmed using Fourier-transform infrared spectroscopy and X-ray diffraction, and thermal evaluation of the material showed stability above 210 °C. Flow cytometry was used to evaluate cell integration and biological activity. Studies have shown low cytotoxicity of scaffolds based on PCL-PEG 70:30 (w/w) interacting with SVF cells, with viability higher than 95%. The scaffolds based on PCL-PEG 70:30 (w/w) did not exhibit cytotoxic characteristics and did not interfere with cell proliferation. Scaffolds based on PCL-PEG 70:30 (w/w) showed favorable kinetics of interaction with the bone lesions of C57BL6J mice, accelerating the lesion closure process and facilitating the formation of new bon
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.